logo
A boomer quit nursing to live on $2,972 monthly in Social Security in an RV in America's parks: 'I literally live in heaven'

A boomer quit nursing to live on $2,972 monthly in Social Security in an RV in America's parks: 'I literally live in heaven'

When Marian Barry's mother died in 2014, the Arizona nurse knew she needed a change. For years, her life had revolved around taking care of her aging parents and working as a cardiac nurse just outside Phoenix.
A colleague suggested travel nursing — well-paid work that would let her explore the country. After three months in Alaska, Barry knew it was the life for her. She sold her house of 16 years in Mesa, bought an RV she named Myrna, and roamed the Western US, working in a slew of hospitals and meeting all sorts of people along the way.
She "absolutely loved" being a nurse and thought she'd work well into her golden years. But when the pandemic hit, that changed. Watching countless patients suffer and die without family at their bedside was agonizing. "It was hell. It was horrible being in the hospital," Barry said.
After 30 years of nursing, she started thinking about retirement. She'd stayed in some national and state parks while travel nursing and noticed that the park employees and volunteers she'd met seemed remarkably happy. So, she applied for a seasonal volunteer gig at Diamond Lake in Oregon.
"After coming out of working the first 15 months of COVID in hospitals, it was like, 'Oh my gosh, I'm in nature. This is amazing. No mask, no PPE,'" she said.
Now, she's a full-time so-called "work-camper," living and volunteering in parks with other itinerant folks like her, many of them also retirees. She spends her days kayaking, biking, and orienting visitors in the parks. She's letting her nursing license expire next year.
"I just cannot imagine going back to any kind of stressful job," Barry, now 71, added.
Barry is part of a much bigger trend. Work-camping in America's parks is a long-established lifestyle, particularly for older people in need of low-cost living or adventure, or both. But as Americans live longer and face rising housing costs on fixed or low incomes, it's only becoming more attractive.
Living off Social Security
Barry made good money as a nurse, but she doesn't have much in savings. So she lives off her monthly $2,972 Social Security checks. She's managing for now and is even splurging on a rental car for the summer.
Living in an RV is pretty cheap. At the campgrounds, she gets a free full hook-up — including water, electricity, and sewer — in exchange for her work.
She says it's been easy for her to live in a tiny space because she's "never been a things kind of person." And she spends much of her time outside.
For the past four years, Barry has spent October through April at Pahranagat National Wildlife Refuge in Nevada, 90 miles north of Vegas, and May through August at Beaver Creek State Natural Area on the coast of central Oregon. She takes September off for vacation.
She loves the dramatic landscapes and has become a wildlife enthusiast.
"I literally live in heaven," Barry said. "I absolutely love my life."
She says she doesn't get lonely because she's made friends with her fellow volunteers and employees. And she spends her days chatting up visitors. "I like to talk to everybody," she said.
Barry has become particularly popular in Oregon, where a beloved breed of blackberry, the marionberry, is grown. Locals and park visitors get a kick out of her name.
"Every day when I say what my name is, they're like, 'Oh, I'll never forget that,'" she said. "I'm like a celebrity here."
One group of fans brought her a marionberry pie.
Barry, who never married or had kids, hopes to keep living in the parks in Oregon and Nevada for the rest of her life. Her siblings and other family members are scattered across the country.
She jokes with one of her nieces, who lives on a farm in Indiana, that if she ever loses the ability to live independently, she'll park her RV in a field on her property and live out her days there.
"Honestly, I have no long-term plan, that's just a fun thing to think about," she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding
Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding

Yahoo

time33 minutes ago

  • Yahoo

Foundation CEO Provides Expert Testimony to U.S. Senate as Outside Witness on Vision Research Funding

Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status COLUMBIA, Md., June 13, 2025 /PRNewswire/ -- The Foundation Fighting Blindness, the driving force in the global development of treatments and cures for blinding diseases, today submitted written testimony to the U.S. Senate Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies through its chief executive officer, Jason Menzo, who served as an expert outside witness. In the testimony, Menzo urged the Subcommittee to deliver robust and sustained funding for the National Eye Institute (NEI) in Fiscal Year 2026 and to preserve NEI's status as an independent institute within the National Institutes of Health (NIH). "NEI is the only federal institute dedicated exclusively to vision research," said Jason Menzo, CEO of the Foundation Fighting Blindness. "Its work is restoring sight, advancing precision medicine, and delivering hope to millions of Americans living with retinal diseases. Continued investment is critical to maintaining momentum and achieving breakthroughs for conditions that currently have no cure." The Foundation's testimony highlights how NEI-supported research has led to transformative discoveries, including the first FDA-approved gene therapy for an inherited disease, and emphasizes NEI's strategic role in public-private collaborations that accelerate treatment development. The Foundation Fighting Blindness and NEI have long shared a close, collaborative partnership to advance high-impact scientific discovery and bring new treatments to patients faster. Vision loss from diseases such as retinitis pigmentosa, macular degeneration, and Stargardt disease currently affects tens of millions and costs the U.S. economy an estimated $134.2 billion annually. The Foundation emphasized that inconsistent funding stalls clinical trials, closes labs, and risks losing top scientific talent—consequences that are difficult and costly to reverse. The testimony also noted that for every dollar invested in NIH-funded research, $2.56 in new economic activity is generated, making this one of the highest-return investments Congress can make. "We're not just talking about restoring sight—we're talking about protecting America's leadership in biomedical innovation and supporting economic growth in communities nationwide," added Menzo. The Foundation Fighting Blindness urges Congress to: Provide strong, sustained funding for NEI in the FY2026 Labor-HHS Appropriations bill; and Preserve NEI's status as an independent institute within NIH to ensure focused, strategic investment in vision science. The full testimony is available at About the Foundation Fighting BlindnessEstablished in 1971, the Foundation Fighting Blindness is the world's leading private source of funding for research on retinal degenerative diseases. The Foundation has raised over $954 million toward its mission to prevent, treat, and cure blinding diseases such as retinitis pigmentosa, age-related macular degeneration, Usher syndrome, and more. Visit for more information. Media Contacts:Chris AdamsVice President, Marketing & CommunicationsCAdams@ 423-0585 View original content to download multimedia: SOURCE Foundation Fighting Blindness

BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

Yahoo

timean hour ago

  • Yahoo

BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. COVID vaccine maker BioNTech is buying rival CureVac, announcing Thursday an all-stock deal weeks before the two companies were due to face off in a German court over potentially billions of dollars worth of royalties related to intellectual property on messenger RNA drugs. Per deal terms, each CureVac share will be exchanged for about $5.46 worth of BioNTech's U.S.-listed shares, valuing the company at $1.25 billion. Upon the deal's close, CureVac shareholders will own between 4% and 6% of BioNTech. In the early days of the COVID-19 pandemic, BioNTech and CureVac were among the companies racing to develop the first coronavirus vaccines. BioNTech, however, partnered with Pfizer and won approval of the first COVID-19 shot, while CureVac's program never made it to market. The two companies have since been embroiled in patent litigation. CureVac was a leading candidate to develop the first COVID-19 vaccine, launching rumors, later denied, that the U.S. government might even buy the company or its research. But while BioNTech and fellow mRNA drugmaker Moderna succeeded in making vaccines that saved millions of lives and earned billions of dollars in revenue, CureVac fell short. Its initial project wasn't effective enough at preventing sickness, prompting it to scrap development. A year later, CureVac sued BioNTech, claiming it infringed four patents. CureVac has since changed course, selling off most rights to influenza and COVID-19 vaccines to partner GSK and focusing on cancer instead. But its legal spat with BioNTech has lingered. The European Patent Office had upheld two CureVac patents, and a trial in a Dusseldorf regional court was set on July 1 to determine if BioNTech had infringed on them. A separate trial in the U.S. was scheduled to begin Sept. 8 in Virginia. Some Wall Street analysts, as a result, speculated that BioNTech's primary purpose is buying CureVac is to sidestep the risk of a loss in court. A single-digit percentage royalty awarded to CureVac could've cost BioNTech as much as $3 billion, Evercore ISI analyst Umer Raffat wrote in a note to clients. 'It seems to us that [BioNTech] assessed the cost of a cash settlement as substantially greater than the cost of buying [CureVac] outright,' Raffat wrote. The deal could also help BioNTech further its oncology ambitions. Like CureVac, BioNTech has made cancer research a top priority. It's invested in a variety of programs, from cell therapies to mRNA vaccines and a coveted type of bispecific antibody. Some are in advanced testing. CureVac's cancer vaccines are in earlier phases of development. A brain cancer shot has delivered early clinical data, while a lung cancer immunotherapy was cleared in April for human testing. The deal should help CureVac because of 'the early stage of the oncology pipeline and the need for a development partner to effectively compete in personalized cancer vaccines – which [BioNTech] is well positioned to execute,' wrote Leerink Partners analyst Mani Foroohar. Raffat, of Evercore ISI, however, wrote that the deal ascribes 'very little value' to CureVac's pipeline. Recommended Reading Recursion to acquire two Canadian drug discovery startups Sign in to access your portfolio

Decisely Notifies Individuals of Data Security Incident
Decisely Notifies Individuals of Data Security Incident

Yahoo

timean hour ago

  • Yahoo

Decisely Notifies Individuals of Data Security Incident

ALPHARETTA, Ga., June 13, 2025 /PRNewswire/ -- Decisely learned of a data security incident that may have involved personal and/or protected health information of certain individuals and has taken steps to notify individuals for whom an address could be found. Recently, we learned that some personal and/or protected health information may have been involved in a data security incident we experienced. The incident began on December 17, 2024, when we discovered suspicious activity related to our cloud storage platform. We promptly took steps to secure the environment and began an investigation to determine the nature and scope of the issue. We engaged cybersecurity experts to conduct an investigation into what happened and to assist us with determining whether personal information was accessed or acquired without authorization. The investigation determined that some data may have been acquired on December 16, 2024. We then completed a comprehensive analysis of the data potentially involved to identify what personal and/or protected health information was impacted and to whom it belonged. We also notified associated owners of the data and worked with them to determine contact information necessary to provide this notice of what happened. Please note that we have no evidence of fraudulent misuse, or attempted misuse, of the potentially impacted information. Based on the review of potentially impacted data, the following information may have been affected as a result of the incident: names, dates of birth, phone number, passport number, digital signature, and/or Social Security numbers. Individuals began receiving notification of this incident on June 13, 2025. Decisely is offering individuals whose Social Security number was involved access to credit monitoring and fully managed identity theft recovery services through Kroll. We have established a toll-free call center to answer questions about the incident and address related concerns. Call center representatives are available Monday through Friday from 8:00 am to 5:30 pm Central Time, and can be reached at (866) 461-3640. As soon as we discovered the incident, we took the steps discussed above to investigate the incident and to notify appropriate individuals. To reduce the likelihood of a similar incident occurring in the future, we also implemented additional measures to enhance the security of our network environment. The privacy and protection of personal and protected health information is a top priority for Decisely, and we appreciate everyone's patience as we respond to this incident. View original content: SOURCE Decisely Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store